Jason Coloma Sells 34,501 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $31.26 on Friday. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -12.36 and a beta of 2.14. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average is $26.02 and its two-hundred day moving average is $35.64. Maze Therapeutics, Inc. has a 52-week low of $10.98 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Analysts forecast that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MAZE. Seven Fleet Capital Management LP acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at about $917,000. Bank of America Corp DE raised its stake in Maze Therapeutics by 961.3% during the first quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock worth $5,823,000 after acquiring an additional 176,703 shares during the period. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares during the last quarter. Exome Asset Management LLC bought a new position in Maze Therapeutics in the first quarter worth about $2,642,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Maze Therapeutics by 111.3% in the first quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after acquiring an additional 7,673 shares during the period.

Analyst Ratings Changes

MAZE has been the subject of several research analyst reports. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Truist Financial reduced their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wedbush upped their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.